In light of the role of CDK4/6is in increasing PD-L1 expression, there is potential for combining CDK4/6is with the PD-1/PD-L1 immune checkpoint blockade to improve therapeutic effectiveness in cancer treatment. The gene discussed is CD274; the disease is cancer.